ReviewNature reviews. Cardiology2011
Novel HDL-directed pharmacotherapeutic strategies.
Review in Nature reviews. Cardiology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 78 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
78 citing papers in PubMed, 148 citations in OpenAlex.
- Infusion of Reconstituted High-Density Lipoprotein, CSL112, in Patients With Atherosclerosis: Safety and Pharmacokinetic Results From a Phase 2a Randomized Clinical Trial.Journal of the American Heart Association · 2015Trial
- Radiolabeling lipoproteins to study and manage disease.European journal of nuclear medicine and molecular imaging · 2025Review
- The Essence of Lipoproteins in Cardiovascular Health and Diseases Treated by Photodynamic Therapy.Biomedicines · 2024Review
- HDL functionality is dependent on hepatocyte stress defense factors Nrf1 and Nrf2.Frontiers in physiology · 2023Article
- High residual cardiovascular risk after lipid-lowering: prime time for Predictive, Preventive, Personalized, Participatory, and Psycho-cognitive medicine.Frontiers in cardiovascular medicine · 2023Review
- Crosstalk Between Cholesterol, ABC Transporters, and PIP2 in Inflammation and Atherosclerosis.Advances in experimental medicine and biology · 2023Article
- The Roles of Fatty Acids and Apolipoproteins in the Kidneys.Metabolites · 2022Review
- A modular approach toward producing nanotherapeutics targeting the innate immune system.Science advances · 2021Article
- Endothelial Lipase Exerts its Anti-Atherogenic Effect through Increased Catabolism of β-VLDLs.Journal of atherosclerosis and thrombosis · 2021Article
- High Density Lipoproteins: Metabolism, Function, and Therapeutic Potential.Frontiers in cardiovascular medicine · 2020Review
- Recent Advances in the Critical Role of the Sterol Efflux Transporters ABCG5/G8 in Health and Disease.Advances in experimental medicine and biology · 2020Review
- Review
- Characterization of apolipoprotein A-I peptide phospholipid interaction and its effect on HDL nanodisc assembly.International journal of nanomedicine · 2019Article
- Creatine kinase, energy reserve, and hypertension: from bench to bedside.Annals of translational medicine · 2018Review
- Efficacy and safety assessment of a TRAF6-targeted nanoimmunotherapy in atherosclerotic mice and non-human primates.Nature biomedical engineering · 2018Article
- Potential role of new molecular plasma signatures on cardiovascular risk stratification in asymptomatic individuals.Scientific reports · 2018Article
- The role of monocytosis and neutrophilia in atherosclerosis.Journal of cellular and molecular medicine · 2018Review
- Preoperative serum apolipoprotein A-I levels predict long-term survival in non-muscle-invasive bladder cancer patients.Cancer management and research · 2018Article
- Increased Hepatic Expression of Endothelial Lipase Inhibits Cholesterol Diet-Induced Hypercholesterolemia and Atherosclerosis in Transgenic Rabbits.Arteriosclerosis, thrombosis, and vascular biology · 2017Article
- Deficiency of Cholesteryl Ester Transfer Protein Protects Against Atherosclerosis in Rabbits.Arteriosclerosis, thrombosis, and vascular biology · 2017Article
18 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
The burden of atherothrombotic cardiovascular disease remains high despite currently available optimum medical therapy. To address this substantial residual risk, the development of novel therapies that attempt to harness the atheroprotective functions of HDL is a major goal. These functions include the critical role of HDL in reverse cholesterol transport, and its anti-inflammatory, antithrombotic, and antioxidant activities. Discoveries in the past decade have shed light on the complex metabolic and antiatherosclerotic pathways of HDL. These insights have fueled the development of HDL-targeted drugs, which can be classified among four different therapeutic approaches: directly augmenting apolipoprotein A-I (apo A-I) levels, such as with apo A-I infusions and upregulators of endogenous apo A-I production; indirectly augmenting apo A-I and HDL-cholesterol levels, such as through inhibition of cholesteryl ester transfer protein or endothelial lipase, or through activation of the high-affinity niacin receptor GPR109A; mimicking the functionality of apo A-I with apo A-I mimetic peptides; and enhancing steps in the reverse cholesterol transport pathway, such as via activation of the liver X receptor or of lecithin-cholesterol acyltransferase.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.